Scrip
FDA says Xolair associated with CV events in interim safety analysis
20 July 2009
Katie McQue
Please Login to read the full article.
20 July 2009
Katie McQue
Initial findings of a safety study of Novartis/ Genentech's asthma drug Xolair (omalizumab) have found a disproportionate increase in cardiovascular and cerebrovascular events in patients taking Xolair compared with those on placebo.
The US FDA has said it would not recommend any changes...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
